BSX vs DXCM: Boston Scientific and DexCom compared
The short version
From the latest prices and each company's SEC filings. Who's ahead on each measure, not which to buy.
- Boston Scientific is the larger company, worth $63.1B, about 1.6 times DexCom.
- DexCom grew revenue faster over the last year (+13.1% vs +7.5%).
- DexCom keeps more of each dollar of revenue as operating profit (22.9% vs 19.8%).
- On earnings, Boston Scientific is the cheaper stock (17.8x vs 41.2x).
- DexCom's price assumes faster free cash flow growth: about 13% a year, against 3% for Boston Scientific (reverse DCF).
Side by side
The stronger figure is shaded where higher (or, for valuation multiples, lower) reads as better. How the implied growth works.
| Measure | BSX | DXCM |
|---|---|---|
| Market cap | $63.1B | $39.6B |
| Share price | $42.73 | $84.11 |
| Revenue (last fiscal year) | $20.1B | $4.7B |
| Free cash flow (last fiscal year) | $3.7B | $1.1B |
| Revenue growth, last year | +7.5% | +13.1% |
| Revenue growth per year, last 5 fiscal years | +14.0% | +17.5% |
| Operating margin | 19.8% | 22.9% |
| Net margin | 17.5% | 20.1% |
| Return on equity | 14.7% | 38.1% |
| P/E (trailing) | 17.8x | 41.2x |
| Price / free cash flow | 17.2x | 36.7x |
| EV / EBITDA | 13.2x | 23.6x |
| FCF growth the price implies | 3.1% | 13.0% |
| Dividend yield | — | — |
| Debt / equity | 0.80x | 1.46x |
| Fundamental grade | B | B |
| Superinvestors holding it | 10 | 5 |
| Insider purchases, last 12 months | 10 | 10 |
Results from SEC filings
Revenue and free cash flow by fiscal year, from each company's 10-K filings.
Boston Scientific
| Year | Revenue | Free cash flow | Op. margin |
|---|---|---|---|
| 2021 | $11.9B | $1.3B | 10.1% |
| 2022 | $12.7B | $938M | 13.0% |
| 2023 | $14.2B | $1.8B | 16.5% |
| 2024 | $16.7B | $2.6B | 15.5% |
| 2025 | $20.1B | $3.7B | 18.0% |
DexCom
| Year | Revenue | Free cash flow | Op. margin |
|---|---|---|---|
| 2021 | $2.4B | $53M | 10.9% |
| 2022 | $2.9B | $305M | 13.4% |
| 2023 | $3.6B | $512M | 16.5% |
| 2024 | $4.0B | $631M | 14.9% |
| 2025 | $4.7B | $1.1B | 19.6% |
Where the revenue comes from
Boston Scientific · by segments, 2025
Cardiovascular$13.2B66%
MedSurg$6.8B34%
DexCom · by regions, 2025
United States$3.3B72%
International$1.3B28%
Compare them in fullFifteen years of statements, quarterly results, DCF and IRR models, and any number of peers side by side.
Open BSX in InvestinglyQuestions
Which is bigger, Boston Scientific or DexCom?
Boston Scientific (BSX), at $63.1B against $39.6B.
Is BSX or DXCM cheaper?
By trailing P/E, Boston Scientific (17.8x) is cheaper than DexCom (41.2x). A lower multiple can also mean the market expects less growth.
Which grows faster, BSX or DXCM?
DexCom: revenue grew +13.1% over the last year, against +7.5%.
Prices and ratios as of the last daily update; statements from SEC filings. Information only, not investment advice.